219 related articles for article (PubMed ID: 23810180)
21. [Procedure for the marketing authorization of an antibacterial agent].
López Navas A; García-Escribano Ráez N; Flores Juberías Á; Suárez Gea ML
Enferm Infecc Microbiol Clin; 2014 Oct; 32(8):529-32. PubMed ID: 25124488
[TBL] [Abstract][Full Text] [Related]
22. Superior efficacy of new medicines?
van Luijn JC; Gribnau FW; Leufkens HG
Eur J Clin Pharmacol; 2010 May; 66(5):445-8. PubMed ID: 20224944
[TBL] [Abstract][Full Text] [Related]
23. Impact of the European paediatric legislation in paediatric rheumatology: past, present and future.
Ruperto N; Vesely R; Saint-Raymond A; Martini A;
Ann Rheum Dis; 2013 Dec; 72(12):1893-6. PubMed ID: 23962457
[TBL] [Abstract][Full Text] [Related]
24. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
25. Enabling Development of Paediatric Medicines in Europe: 10 Years of the EU Paediatric Regulation.
Tomasi PA; Egger GF; Pallidis C; Saint-Raymond A
Paediatr Drugs; 2017 Dec; 19(6):505-513. PubMed ID: 28900869
[TBL] [Abstract][Full Text] [Related]
26. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer.
Vassal G; Rousseau R; Blanc P; Moreno L; Bode G; Schwoch S; Schrappe M; Skolnik J; Bergman L; Bradley-Garelik MB; Saha V; Pearson A; Zwierzina H
Eur J Cancer; 2015 Jan; 51(2):218-24. PubMed ID: 25434924
[TBL] [Abstract][Full Text] [Related]
27. [New drugs in oncology--features of clinical trials for market authorisation and arguments for the rapid implementation of independent clinical trials following approval].
Ludwig WD; Schott G
Onkologie; 2013; 36 Suppl 2():17-22. PubMed ID: 23549032
[TBL] [Abstract][Full Text] [Related]
28. Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2014.
Deane BR; Porkess S
Curr Med Res Opin; 2018 Jul; 34(7):1239-1243. PubMed ID: 29219621
[TBL] [Abstract][Full Text] [Related]
29. The challenge of antimicrobial resistance: new regulatory tools to support product development.
Tomayko JF; Rex JH; Tenero DM; Goldberger M; Eisenstein BI
Clin Pharmacol Ther; 2014 Aug; 96(2):166-8. PubMed ID: 24823890
[TBL] [Abstract][Full Text] [Related]
30. Medicines for children licensed by the European Medicines Agency (EMEA): the balance after 10 years.
Ceci A; Felisi M; Baiardi P; Bonifazi F; Catapano M; Giaquinto C; Nicolosi A; Sturkenboom M; Neubert A; Wong I
Eur J Clin Pharmacol; 2006 Nov; 62(11):947-52. PubMed ID: 17021892
[TBL] [Abstract][Full Text] [Related]
31. Antibiotic prescribing for upper respiratory infections: European primary paediatricians' knowledge, attitudes and practice.
Grossman Z; del Torso S; Hadjipanayis A; van Esso D; Drabik A; Sharland M
Acta Paediatr; 2012 Sep; 101(9):935-40. PubMed ID: 22716070
[TBL] [Abstract][Full Text] [Related]
32. ECNP consensus meeting. Bipolar depression. Nice, March 2007.
Goodwin GM; Anderson I; Arango C; Bowden CL; Henry C; Mitchell PB; Nolen WA; Vieta E; Wittchen HU
Eur Neuropsychopharmacol; 2008 Jul; 18(7):535-49. PubMed ID: 18501566
[TBL] [Abstract][Full Text] [Related]
33. Changes in availability of paediatric medicines in Australia between 1998 and 2002.
Chui J; Tordoff J; Reith D
Br J Clin Pharmacol; 2005 Jun; 59(6):736-42. PubMed ID: 15948941
[TBL] [Abstract][Full Text] [Related]
34. Antibiotic discovery in the twenty-first century: current trends and future perspectives.
Donadio S; Maffioli S; Monciardini P; Sosio M; Jabes D
J Antibiot (Tokyo); 2010 Aug; 63(8):423-30. PubMed ID: 20551985
[TBL] [Abstract][Full Text] [Related]
35. Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antibacterial Agents: A Review.
Jorda A; Zeitlinger M
Clin Pharmacokinet; 2020 Sep; 59(9):1071-1084. PubMed ID: 32356105
[TBL] [Abstract][Full Text] [Related]
36. Three years of paediatric regulation in the European Union.
Olski TM; Lampus SF; Gherarducci G; Saint Raymond A
Eur J Clin Pharmacol; 2011 Mar; 67(3):245-52. PubMed ID: 21286912
[TBL] [Abstract][Full Text] [Related]
37. Trends in paediatric clinical pharmacology data in US pharmaceutical labelling.
Samiee-Zafarghandy S; Mazer-Amirshahi M; van den Anker JN
Arch Dis Child; 2014 Sep; 99(9):862-5. PubMed ID: 25063835
[TBL] [Abstract][Full Text] [Related]
38. Regulatory aspects of clinical trials in children.
Mentzer D
Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009; 96():203-7; discussion 207-9. PubMed ID: 20799462
[TBL] [Abstract][Full Text] [Related]
39. A prospective questionnaire assessment of attitudes and experiences of off label prescribing among hospital based paediatricians.
McLay JS; Tanaka M; Ekins-Daukes S; Helms PJ
Arch Dis Child; 2006 Jul; 91(7):584-7. PubMed ID: 16443615
[TBL] [Abstract][Full Text] [Related]
40. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
